Abstract
Cannabis, an ancient plant that has been used for millennia, is increasingly utilized by patients with cancer to alleviate symptoms related to both the disease and its treatment. This complex botanical contains multiple bioactive compounds, most notably delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), which interact with the endogenous endocannabinoid system. THC has been studied the most, and synthetic cannabinoids are approved for the management of chemotherapy-induced nausea and vomiting. However, evidence supporting cannabis for other cancer-related symptoms—including chemotherapy-induced peripheral neuropathy, insomnia, appetite stimulation, and non-neuropathic pain—remains limited. CBD alone has not demonstrated consistent or meaningful clinical benefit. Although preclinical data exist, there is no clinical evidence supporting cannabis as a cancer treatment. Cannabis may interact with prescribed medications, particularly with high-dose oral formulations, and its effects on immunotherapy are under investigation. Overall, cannabis is generally well tolerated, though adverse effects can be significant. Use is discouraged in individuals under 25 years of age due to ongoing neurodevelopment, and patients with active psychiatric or cardiovascular conditions should use cannabis only under close clinical supervision.
Keywords: cancer, cannabidiol, cannabis, delta-9-tetrahydrocannabinol, endocannabinoid system
Introduction
Cannabis has been used medicinally for millennia, with documentation in ancient Ayurvedic texts and the Chinese Shen Nung Pen Ts’ao Ching, one of the earliest pharmacopoeias (1, 2). The endocannabinoid system (ECS) is a highly conserved biological network composed of endogenous ligands, cannabinoid receptors, and enzymes responsible for their synthesis and degradation (3, 4). Present across a wide range of species, the ECS plays a central role in maintaining homeostasis, influencing neural signaling, immune modulation, learning, memory, sleep, appetite, temperature regulation, pain perception, and stress responses. Although plants do not possess an ECS, the cannabis plant produces cannabinoid-like compounds that interact with this system (5–7).
Cannabis is a complex botanical containing over 400 chemical compounds, including more than 100 cannabinoids. Delta-9-tetrahydrocannabinol (THC) is the primary psychoactive component, while cannabidiol (CBD) is non-psychoactive and widely used despite limited clinical evidence (8–10). Other cannabinoids, such as cannabigerol (CBG) and tetrahydrocannabivarin, remain under investigation (11–13). Terpenoids and flavonoids contribute to the plant’s sensory properties and may play a role in the proposed “entourage effect.”
Several cannabinoid-based medications have been approved, including dronabinol (14) and nabilone for chemotherapy-induced nausea and vomiting, and CBD (Epidiolex®) for refractory epilepsy. Nabiximols (15), a THC: CBD extract, is approved in multiple countries but not in the United States. Hemp, defined as cannabis containing ≤0.3% THC by dry weight, is legally distinct and widely available, though often poorly regulated (16).
Cannabis potency has increased substantially over recent decades (17), with THC concentrations rising from approximately 4% in the mid-1990s to over 15–17% in recent years, accompanied by a marked increase in the THC: CBD ratio. These changes have important implications for both therapeutic effects and potential adverse outcomes.
As of 2026, most U.S. states permit medical cannabis use, with comprehensive programs in approximately 40 states, while 24 states and Washington, DC allow adult recreational use (16).
Prevalence of cannabis use in cancer patients
Cannabis use is common among patients with cancer, with surveys estimating prevalence rates of approximately 25–36%. In a Northern California survey of 2, 602 patients, 24.7% reported cannabis use, most commonly for sleep (56.7%), with many reporting perceived symptom improvement (18). Similar findings have been reported in surveys from Fred Hutch/University of Washington (19) Stephenson Cancer Center in Oklahoma (20), where patients reported benefit for insomnia, pain, stress, nausea, and mood symptoms. Notably, approximately 18% of respondents reported using cannabis with the intent of treating their cancer.
Mechanism of action
In 1964, Raphael Mechoulam et al. (21) first isolated and characterized delta-9-tetrahydrocannabinol (THC), the primary psychoactive component of cannabis. Cannabinoid receptors (CB1) were identified in 1988 (22), followed in 1992 by the discovery of their endogenous ligand. This was named anandamide after the Sanskrit word “Ananda” or bliss. Anandamide binds primarily to CB1 receptors, mimics many effects of THC, and is synthesized on demand rather than stored. In the mid-1990s, a second major endocannabinoid, 2-arachidonoylglycerol (2-AG), along with key enzymes involved in endocannabinoid synthesis and degradation, including fatty acid amide hydrolase (FAAH), were identified (4).
Endocannabinoids are produced from membrane lipids in postsynaptic neurons and act via retrograde signaling to modulate neurotransmitter release at presynaptic terminals (23). The functions of the endocannabinoid system have been broadly summarized as “relax, eat, sleep, forget and protect.” (24) THC acts as a partial agonist at cannabinoid receptors, whereas CBD functions as a negative allosteric modulator, altering receptor conformation and attenuating the effects of THC and endogenous cannabinoids (8, 9).
Routes of delivery
Cannabis can be delivered in multiple ways including inhalation, ingestion, sublingual, transdermal, topical, rectal, and vaginal routes (25, 26).
The pharmacokinetics vary significantly by route influencing onset, duration, and clinical use. Inhalation by smoking or vaporization produces rapid onset within minutes but a relatively short duration of effect, making it useful for acute symptoms such as breakthrough pain or nausea. In contrast, oral formulations have a delayed onset due to first-pass hepatic metabolism, with effects lasting several hours. This makes them better suited for sustained symptom control, such as pain or sleep disturbance. Sublingual preparations carry an intermediate profile, reflecting a combination of mucosal absorption and subsequent ingestion. Thus, patients may use multiple routes for different effects. Following oral ingestion, first-pass metabolism through the liver converts the delta-9-THC into the more psychoactive 11-hydroxy-THC (11, 27). The delayed onset of action combined with this increased psychoactivity, contribute to a higher risk of side effects in cannabis-naïve users, who may re-dose when an immediate benefit is not perceived with oral ingestion, and may subsequently experience delayed side effects (10, 12).
Cannabis dosing and titration
A wide array of cannabis products is now available, encompassing diverse cannabinoid compositions and ratios. When advising patients, the guiding principle is to “start low and go slow.” Initial THC doses of 2.5–3.0 mg daily are generally considered safe, with lower starting doses (e.g., 1 mg) recommended for older patients. Doses may be titrated gradually every few days (by 1–2.5 mg) based on clinical response and tolerability (25)., Various products with differing THC: CBD ratios, as well as CBD-only products, are currently available. Given the complexity of available formulations, a practical approach is to focus primarily on the THC content and titrate the dose accordingly, as outlined above.
With repeated exposure, CB1 receptors may become desensitized and downregulated (28), leading to reduced clinical effect (tolerance). In such cases, temporary discontinuation may help restore receptor responsiveness. CB1 receptor availability begins to recover rapidly following cannabis cessation (28), with substantial recovery after a four-week abstinence (29, 30). Importantly, not all patients will derive benefit; if meaningful improvement is not observed after an adequate trial, further dose escalation is unlikely to be helpful and may increase adverse effects (13).
Hemp-derived cannabinoid products are widely available but often poorly regulated and may contain contaminants, including synthetic cannabinoids, pesticides, and heavy metals (31, 32). Patients should be advised to obtain products from licensed dispensaries that provide certificates of analysis to ensure quality and safety.
Key uses studied in oncology
Nausea and vomiting
Dronabinol and nabilone were approved as antiemetics in 1986 based on clinical trials conducted in the 1970s and 1980s (33). They were compared to the options available then, and shown to be superior to placebo, and at least as effective as options available at the time. Additionally, more recent analyses of the same studies found them of low quality overall (34, 35).
Now that modern antiemetics like 5-HT3 antagonists and NK1 inhibitors are available, Dronabinol and nabilone have limited clinical use (13).
A Cochrane review concluded that cannabis-based medications may be useful in treating refractory chemotherapy-induced nausea and vomiting (35). Small, randomized trials provide modest support.
However, data on botanical cannabis remain limited and inconclusive and much of the perceived benefit is anecdotal. Current ASCO guidelines recommend that cannabinoids may be considered as adjunctive therapy for refractory chemotherapy-induced nausea and vomiting in patients receiving guideline-concordant antiemetics, though this is a weak recommendation based on low- to moderate-quality evidence (13).
Anorexia and cachexia
Recreational users of cannabis often report increased appetite, colloquially referred to as “the munchies.” This led to an interest in looking at the role of cannabis in anorexia and cachexia. A randomized, double-blind trial of dronabinol versus megestrol versus the combination in 469 patients with cancer cachexia failed to show benefit for dronabinol. The combination was also inferior to megestrol alone (36). Subsequent studies have shown cannabinoids increased appetite and caloric intake but not weight gain (37, 38). Clinical evidence for botanical cannabis products in cancer-associated anorexia and cachexia remains very limited.
Pain
The endocannabinoid system is felt to play a key role in responses to pain (39). The National Academies of Sciences, Engineering, and Medicine (NASEM) concluded that “there is substantial evidence that cannabis is an effective treatment for chronic pain in adults.” (40) Preclinical evidence suggests that cannabinoids may be beneficial in both the treatment and prevention of chemotherapy-induced peripheral neuropathy (CIPN) (41, 42).
Preclinical studies also suggest synergy between cannabinoids and opioids in producing analgesia (43). Limited clinical data suggest cannabis may stabilize or reduce opioid requirements (44, 45) without altering opioid pharmacokinetics much. However, effects on pain control have been modest and inconsistent. At present, the evidence remains mixed, and clinically meaningful opioid-sparing or opioid-replacement effects have not been conclusively demonstrated.
Quality of life
As seen in the various survey studies cited earlier, cannabis-based products are frequently used for insomnia, anxiety, depression, and other quality-of-life-related patient-reported outcome measures. However, evidence remains limited (19, 20). CBD alone in particular has not shown improvement in quality of life (46). Most studies of combined THC: CBD formulations have also failed to show significant benefit in overall symptom distress compared to placebo. Overall, while some patients report subjective improvement, high-quality evidence supporting cannabinoids for these indications remains lacking (13, 46, 47).
Cannabis as an anti-cancer agent
Survey data suggest that 10–25% of patients with cancer use cannabis with the intent of achieving a cure (18), and in one study, up to 49% of patients with breast cancer held this belief (48). This is likely influenced by claims circulating on the internet and social media (49). Full Extract Cannabis Oil (FECO, or Rick Simpson Oil), a high-dose THC concentrate, is frequently marketed for anticancer use via oral or rectal administration. However, a comprehensive review of case reports found that 86% lacked sufficient data to support such claims (50).
A study tried to find out how cannabis may help control cancer growth by reviewing medical records of patients who reported cannabis helped treat their cancer, but only about a dozen responses were received despite heavy advertising. This highlights the rarity of such cases and suggests that these instances may be far more uncommon than is generally perceived (51).
Preclinical findings: Cannabinoids have demonstrated antitumor activity in multiple cell lines and animal models. Proposed mechanisms include induction of apoptosis, inhibition of vascular endothelial growth factor (VEGF), and suppression of matrix metalloproteinase-2, which is involved in tumor invasion and metastasis (52–54).
Clinical evidence: Given the high density of CB1 receptors in the central nervous system, clinical trials have largely focused on glioblastoma (55–57). These studies have been small and have produced mixed results. Larger, more definitive trials are ongoing (58).
The National Academies of Sciences, Engineering, and Medicine (NASEM) concluded that there is insufficient clinical evidence to support anticancer activity (40).
Safety considerations
Cannabis use has been associated with alterations in cortical development, particularly affecting the prefrontal cortex, which continues to mature into the mid-20s. As a result, use before age 25 is discouraged due to potential long-term neurocognitive effects (13). Increasing cannabis potency over recent decades has also raised concerns regarding adverse effects (17).
Although generally well tolerated, cannabis can affect multiple organ systems, including cardiovascular, respiratory, hepatic, and neurocognitive function (10). Acute use may impair reaction time, coordination, cognition, and perception (10), while chronic use has been associated with deficits in attention, memory, and executive function (10, 12).
THC-containing products (typically at doses >2.5 mg) may cause dizziness, dry mouth, euphoria, conjunctival injection, altered blood pressure, and tachycardia (12). Mild withdrawal symptoms occur in up to 50% of daily users and may include insomnia, restlessness, nausea, and irritability. CBD is generally better tolerated but, at higher doses (>300 mg/day), may cause gastrointestinal symptoms, fatigue, and elevated liver enzymes; current guidelines recommend avoiding such doses outside of clinical trials (12, 13).
Risk of dependence
The risk of cannabis dependence has historically been estimated at approximately 9–10% among people who use cannabis, although estimates vary according to population, frequency of use, and age at initiation (29, 59).
Risk of cancer
The association between cannabis use and lung or head and neck cancers is uncertain, with observational studies reporting inconsistent findings (60). Some observational studies suggest increased risk in individuals with cannabis use disorder; however, these findings are confounded by concurrent tobacco and alcohol use (60). More recent analyses have not demonstrated a consistent association between cannabis use and urologic cancers (61), though some findings warrant further investigation.
Drug botanical interactions
Formal pharmacokinetic interaction evaluation between cannabis and cancer therapies is scarce (13, 62). THC, CBD, and several other cannabinoids are metabolized by cytochrome P450 isoforms. CBD is an inhibitor of CYP3A4 and also affects CYP2C19 and CYP2D6, pathways involved in the metabolism of many cancer therapies (63–65). Cannabis tea was found not to have a significant pharmacokinetic effect on docetaxel or irinotecan concentrations (66), but tea is an infrequently used modality by most patients. The potential for clinically meaningful interactions may be greater with highly concentrated oral cannabinoid products (63, 64). While concomitant cannabis use could theoretically increase exposure to certain anticancer therapies, particularly through CYP-mediated interactions, clinically significant effects appear most likely with high-dose CBD products, which we generally do not recommend.
Effect on immunotherapy
Cannabis may interact with immunotherapy, as CB2 receptors are abundant on immune cells (3). In a 2020 observational study of 102 patients with stage IV cancer, Bar-Sela et al. reported worse outcomes with cannabis use: progression-free survival 3.4 vs 13.1 months and overall survival 6.5 vs 28.5 months, with fewer immune-related adverse events suggesting reduced treatment activity (67).
However, subsequent studies are less concerning. An analysis by Waissengrin et al. (68) found no statistically significant differences in outcomes among patients with non–small-cell lung cancer treated with pembrolizumab, though cannabis users had more liver and brain metastases. Larger retrospective analyses, including a cohort of 3, 883 immunotherapy-treated patients (13.3% cannabis users), also found no survival difference (HR 1.03; p=0.67) (69).
Overall, evidence is mixed; patients receiving immunotherapy, especially for curative intent, should be advised that the effects of concurrent cannabis use remain uncertain (13, 67–69).
Conclusion
High-quality evidence is limited, but with further study, it appears botanical cannabis could be a potentially useful adjunct for managing cancer-related symptoms and treatment side effects. While adverse effects can be distressing and use in patients under the age of 25 should be discouraged, cannabis appears to be generally well tolerated. However, while some preclinical data may suggest possible antitumor effects, there is no convincing clinical evidence to support cannabis as an anticancer treatment.
Potential drug interactions, particularly with concentrated oral THC and CBD products, should be considered. The impact of cannabis use during immunotherapy remains unclear. Patients being treated with curative intent should especially be counseled regarding this uncertainty. As regulatory barriers evolve, expanded clinical research will be essential to better define the therapeutic role, safety, and limitations of cannabis in oncology.
Funding Statement
The author(s) declared that financial support was not received for this work and/or its publication.
Footnotes
Edited by: Ting Bao, City of Hope National Medical Center, United States
Reviewed by: Massimo Bonucci, Fondazione Artoi, Italy
Alva Weir, United States Department of Veterans Affairs, United States
Author contributions
DB: Data curation, Investigation, Writing – original draft, Writing – review & editing. DA: Writing – original draft, Writing – review & editing. DZ: Writing – original draft, Writing – review & editing. SD: Conceptualization, Data curation, Resources, Writing – original draft, Writing – review & editing.
Conflict of interest
Author DZ was employed by HealthPartners Inc.
The remaining author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was used in the creation of this manuscript. Generative AI was used only to spell check, shorten text and correct grammatical errors.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
- 1. Pisanti S, Bifulco M. Medical cannabis: a plurimillennial history of an evergreen. J Cell Physiol. (2019) 234:8342–51. [DOI] [PubMed] [Google Scholar]
- 2. Crocq MA. History of cannabis and the endocannabinoid system. Dialogues Clin Neurosci. (2020) 22:223–8. doi: 10.31887/dcns.2020.22.3/mcrocq [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Lowe H, Toyang N, Steele B, Bryant J, Ngwa W. The endocannabinoid system: a potential target for the treatment of various diseases. Int J Mol Sci. (2021) 22:9472. doi: 10.3390/ijms22179472 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Martinez Ramirez CE, Ruiz-Pérez G, Stollenwerk TM, Behlke C, Doherty A, Hillard CJ. Endocannabinoid signaling in the central nervous system. Glia. (2023) 71:5–35. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Abrams DI. Cannabis, cannabinoids and cannabis-based medicines in cancer care. Integr Cancer Ther. (2022) 21:15347354221081772. doi: 10.1177/15347354221081772 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. (2015) 313:2456–73. doi: 10.1001/jama.2015.6358 [DOI] [PubMed] [Google Scholar]
- 7. Abrams DI, D’Andre S, Zylla D. Cannabis and cannabinoids in integrative oncology. In: Comprehensive Integrative Oncology. Springer; (2026). p. 549–62. [Google Scholar]
- 8. Dutta S, Selvam B, Das A, Shukla D. Mechanistic origin of partial agonism of tetrahydrocannabinol for cannabinoid receptors. J Biol Chem. (2022) 298:101764. doi: 10.1016/j.jbc.2022.101764 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Stella N. THC and CBD: similarities and differences between siblings. Neuron. (2023) 111:302–27. doi: 10.1016/j.neuron.2022.12.022 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Gorelick DA. Cannabis-related disorders and toxic effects. N Engl J Med. (2023) 389:2267–75. doi: 10.1056/nejmra2212152 [DOI] [PubMed] [Google Scholar]
- 11. Patilea-Vrana GI, Unadkat JD. Quantifying hepatic enzyme kinetics of (-)-Δ9-tetrahydrocannabinol (THC) and its psychoactive metabolite, 11-OH-THC, through in vitro modeling. Drug Metab Dispos. (2019) 47:743–52. doi: 10.1124/dmd.119.086470 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Hsu M, Shah A, Jordan A, Gold MS, Hill KP. Therapeutic use of cannabis and cannabinoids: a review. JAMA. (2026) 335:345–59. [DOI] [PubMed] [Google Scholar]
- 13. Braun IM, Bohlke K, Abrams DI. Cannabis and cannabinoids in adults with cancer: ASCO guideline. J Clin Oncol. (2024) 42:1575–93. doi: 10.1200/jco.23.02596 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Chow R, Basu A, Kaur J, Hui D, Im J, Prsic E, et al. Efficacy of cannabinoids for the prophylaxis of chemotherapy-induced nausea and vomiting-a systematic review and meta-analysis. Support Care Cancer. (2025) 33:193. doi: 10.1007/s00520-025-09251-w [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Wilkie G, Sakr B, Rizack T. Medical marijuana use in oncology: a review. JAMA Oncol. (2016) 2:670–5. [DOI] [PubMed] [Google Scholar]
- 16. National Conference of State L . State Cannabis Legislation Database (2026). Available online at: https://www.ncsl.org/health/state-cannabis-legislation-database (Accessed March 30).
- 17. Chandra S, Radwan MM, Majumdar CG, Church JC, Freeman TP, ElSohly MA. New trends in cannabis potency in USA and Europe during the last decade (2008-2017). Eur Arch Psychiatry Clin Neurosci. (2019) 269:5–15. doi: 10.1007/s00406-019-00983-5 [DOI] [PubMed] [Google Scholar]
- 18. Behl D, D'Andre S, Hankins A, Tiet K, Portugal J, Parise C. Demographics, methods of use, and perceived benefits among patients with cancer who use cannabis. Support Care Cancer. (2026) 34:197. doi: 10.1007/s00520-026-10452-0 [DOI] [PubMed] [Google Scholar]
- 19. Pergam SA, Woodfield MC, Lee CM, Cheng GS, Baker KK, Marquis SR, et al. Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use. Cancer. (2017) 123:4488–97. doi: 10.1002/cncr.30879 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Azizoddin DR, Cohn AM, Ulahannan SV, Henson CE, Alexander AC, Moore KN, et al. Cannabis use among adults undergoing cancer treatment. Cancer. (2023) 129:3498–508. doi: 10.1002/cncr.34922 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Mechoulam R, Gaoni Y. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc. (1964) 86:1646–7. [Google Scholar]
- 22. Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. (1988) 34:605–13. doi: 10.1016/s0026-895x(25)09876-1 [DOI] [PubMed] [Google Scholar]
- 23. Lovinger DM, Mateo Y, Johnson KA, Engi SA, Antonazzo M, Cheer JF. Local modulation by presynaptic receptors controls neuronal communication and behaviour. Nat Rev Neurosci. (2022) 23:191–203. doi: 10.1038/s41583-022-00561-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Di Marzo V, Melck D, Bisogno T, De Petrocellis L. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci. (1998) 21:521–8. doi: 10.1016/s0166-2236(98)01283-1 [DOI] [PubMed] [Google Scholar]
- 25. MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med. (2018) 49:12–9. doi: 10.1016/j.ejim.2018.01.004 [DOI] [PubMed] [Google Scholar]
- 26. Kebede L, Masoomi Dezfooli S, Seyfoddin A. Medicinal cannabis pharmacokinetics and potential methods of delivery. Pharm Dev Technol. (2022) 27:202–14. doi: 10.1080/10837450.2022.2035748 [DOI] [PubMed] [Google Scholar]
- 27. Heuberger JA, Guan Z, Oyetayo OO, Klumpers L, Morrison PD, Beumer TL, et al. Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short- and long-term pharmacokinetics. Clin Pharmacokinet. (2015) 54:209–19. [DOI] [PubMed] [Google Scholar]
- 28. Piscura MK, Henderson-Redmond AN, Barnes RC, Mitra S, Guindon J, Morgan DJ. Mechanisms of cannabinoid tolerance. Biochem Pharmacol. (2023) 214:115665. doi: 10.1016/j.bcp.2023.115665 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Le Foll B, Tang VM, Rueda S, Trick LV, Boileau I. Cannabis use disorder: from neurobiology to treatment. J Clin Invest. (2024) 134:e172887. doi: 10.1172/jci172887 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Hirvonen J, Goodwin RS, Li CT, Terry GE, Zoghbi SS, Morse C, et al. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol Psychiatry. (2012) 17:642–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. Jameson LE, Conrow KD, Pinkhasova DV, Boulanger HL, Ha H, Jourabchian N, et al. Comparison of state-level regulations for cannabis contaminants and implications for public health. Environ Health Perspect. (2022) 130:97001. doi: 10.1289/ehp11206 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Meehan-Atrash J, Rahman I. Novel Δ8-tetrahydrocannabinol vaporizers contain unlabeled adulterants, unintended byproducts of chemical synthesis, and heavy metals. Chem Res Toxicol. (2022) 35:73–6. doi: 10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a1148 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Sallan SE, Zinberg NE, Frei E, 3rd. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med. (1975) 293:795–7. doi: 10.1056/nejm197510162931603 [DOI] [PubMed] [Google Scholar]
- 34. Tramèr MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ. (2001) 323:16–21. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. Smith LA, Azariah F, Lavender VT, Stoner NS, Bettiol S. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev. (2015) 2015:CD009464. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol. (2002) 20:567–73. doi: 10.1200/jco.2002.20.2.567 [DOI] [PubMed] [Google Scholar]
- 37. Razmovski-Naumovski V, Luckett T, Amgarth-Duff I, Agar MR. Efficacy of medicinal cannabis for appetite-related symptoms in people with cancer: a systematic review. Palliat Med. (2022) 36:912–27. doi: 10.1177/02692163221083437 [DOI] [PubMed] [Google Scholar]
- 38. Brisbois TD, de Kock IH, Watanabe SM, Mirhosseini M, Lamoureux DC, Chasen M, et al. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol. (2011) 22:2086–93. doi: 10.1093/annonc/mdq727 [DOI] [PubMed] [Google Scholar]
- 39. Guindon J, Hohmann AG. The endocannabinoid system and pain. CNS Neurol Disord Drug Targets. (2009) 8:403–21. doi: 10.2174/187152709789824660 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40. National Academies of Sciences E, Medicine, Health, Medicine D, Board on Population H, Public Health P, et al. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. National Academies Press; (2017). [PubMed] [Google Scholar]
- 41. Rahn EJ, Deng L, Thakur GA, Vemuri K, Zvonok AM, Lai YY, et al. Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery. Mol Pain. (2014) 10:27. doi: 10.1186/1744-8069-10-27 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42. Khasabova IA, Khasabov S, Paz J, Harding-Rose C, Simone DA, Seybold VS. Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy. J Neurosci. (2012) 32:7091–101. doi: 10.1523/jneurosci.0403-12.2012 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43. Welch SP. Interaction of the cannabinoid and opioid systems in the modulation of nociception. Int Rev Psychiatry. (2009) 21:143–51. doi: 10.1080/09540260902782794 [DOI] [PubMed] [Google Scholar]
- 44. Abrams DI, Couey P, Shade SB, Kelly ME, Benowitz NL. Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther. (2011) 90:844–51. doi: 10.1038/clpt.2011.188 [DOI] [PubMed] [Google Scholar]
- 45. Zylla DM, Eklund J, Gilmore G, Gavenda A, Guggisberg J, VazquezBenitez G, et al. A randomized trial of medical cannabis in patients with stage IV cancers to assess feasibility, dose requirements, impact on pain and opioid use, safety, and overall patient satisfaction. Support Care Cancer. (2021) 29:7471–8. doi: 10.1007/s00520-021-06301-x [DOI] [PubMed] [Google Scholar]
- 46. Hardy J, Greer R, Huggett G, Kearney A, Gurgenci T, Good P. Phase IIb randomized, placebo-controlled, dose-escalating, double-blind study of cannabidiol oil for the relief of symptoms in advanced cancer (MedCan1-CBD). J Clin Oncol. (2023) 41:1444–52. doi: 10.1200/jco.22.01632 [DOI] [PubMed] [Google Scholar]
- 47. Braun IM, Nayak MM, Revette A, Wright AA, Chai PR, Yusufov M, et al. Cancer patients' experiences with medicinal cannabis-related care. Cancer. (2021) 127:67–73. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48. Weiss MC, Hibbs JE, Buckley ME, Danese SR, Leitenberger A, Bollmann-Jenkins M, et al. A Coala-T-Cannabis survey study of breast cancer patients' use of cannabis before, during, and after treatment. Cancer. (2022) 128:160–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49. Shi S, Brant AR, Sabolch A, Pollom E. False news of a cannabis cancer cure. Cureus. (2019) 11:e3918. doi: 10.7759/cureus.3918 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50. Guggisberg J, Schumacher M, Gilmore G, Zylla DM. Cannabis as an anticancer agent: a review of clinical data and assessment of case reports. Cannabis Cannabinoid Res. (2022) 7:24–33. doi: 10.1089/can.2021.0045 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.HealthPartners Institute. Assessing claims of cannabis as an anti-cancer agent (CATA). (2025). Available online at: ClinicalTrials.gov. [Google Scholar]
- 52. Velasco G, Sánchez C, Guzmán M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer. (2012) 12:436–44. doi: 10.1038/nrc3247 [DOI] [PubMed] [Google Scholar]
- 53. Massi P, Solinas M, Cinquina V, Parolaro D. Cannabidiol as potential anticancer drug. Br J Clin Pharmacol. (2013) 75:303–12. doi: 10.1111/j.1365-2125.2012.04298.x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54. Fowler CJ. Delta(9) -tetrahydrocannabinol and cannabidiol as potential curative agents for cancer: a critical examination of the preclinical literature. Clin Pharmacol Ther. (2015) 97:587–96. doi: 10.1002/cpt.84 [DOI] [PubMed] [Google Scholar]
- 55. Guzmán M, Duarte MJ, Blázquez C, Ravina J, Rosa MC, Galve-Roperh I, et al. A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. (2006) 95:197–203. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56. Twelves C, Sabel M, Checketts D, Miller S, Tayo B, Jove M, et al. A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma. Br J Cancer. (2021) 124:1379–87. doi: 10.1038/s41416-021-01259-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57. Schloss J, Lacey J, Sinclair J, Steel A, Sughrue M, Sibbritt D, et al. A phase 2 randomised clinical trial assessing the tolerability of two different ratios of medicinal cannabis in patients with high grade gliomas. Front Oncol. (2021) 11:649555. doi: 10.3389/fonc.2021.649555 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58. Bhaskaran D, Savage J, Patel A, Collinson F, Mant R, Boele F, et al. A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial. BMC Cancer. (2024) 24:83. doi: 10.1186/s12885-023-11792-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59. Schlag AK, Hindocha C, Zafar R, Nutt DJ, Curran HV. Cannabis based medicines and cannabis dependence: a critical review of issues and evidence. J Psychopharmacol. (2021) 35:773–85. doi: 10.1177/0269881120986393 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60. Gallagher TJ, Chung RS, Lin ME, Kim I, Kokot NC. Cannabis use and head and neck cancer. JAMA Otolaryngol Head Neck Surg. (2024) 150:1068–75. doi: 10.1001/jamaoto.2024.2419 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61. Huang J, Huang D, Ruan X, Huang J, Xu D, Heavey S, et al. Association between cannabis use with urological cancers: a population-based cohort study and a mendelian randomization study in the UK biobank. Cancer Med. (2023) 12:3468–76. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62. Sawtelle L, Holle LM. Use of cannabis and cannabinoids in patients with cancer. Ann Pharmacother. (2021) 55:870–90. [DOI] [PubMed] [Google Scholar]
- 63. Kocis PT, Vrana KE. Delta-9-tetrahydrocannabinol and cannabidiol drug-drug interactions. Med Cannabis Cannabinoids. (2020) 3:61–73. doi: 10.1159/000507998 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64. Nachnani R, Knehans A, Neighbors JD, Kocis PT, Lee T, Tegeler K, et al. Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, and cannabis. Front Pharmacol. (2024) 15:1282831. doi: 10.3389/fphar.2024.1282831 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65. Ho JJY, Goh C, Leong CSA, Ng KY, Bakhtiar A. Evaluation of potential drug-drug interactions with medical cannabis. Clin Transl Sci. (2024) 17:e13812. doi: 10.1111/cts.13812 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66. Engels FK, de Jong FA, Sparreboom A, Mathot RA, Loos WJ, Kitzen JJ, et al. Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel. Oncologist. (2007) 12:291–300. doi: 10.1634/theoncologist.12-3-291 [DOI] [PubMed] [Google Scholar]
- 67. Bar-Sela G, Cohen I, Campisi-Pinto S, Lewitus GM, Oz-Ari L, Jehassi A, et al. Cannabis consumption used by cancer patients during immunotherapy correlates with poor clinical outcome. Cancers (Basel). (2020) 12:2447. doi: 10.3390/cancers12092447 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68. Waissengrin B, Leshem Y, Taya M, Meiri D, Merimsky O, Shamai S, et al. The use of medical cannabis concomitantly with immune checkpoint inhibitors in non-small cell lung cancer: a sigh of relief? Eur J Cancer. (2023) 180:52–61. doi: 10.1016/j.ejca.2022.11.022 [DOI] [PubMed] [Google Scholar]
- 69. Behl D, Hankins A, Li J. Impact of cannabis use on survival outcomes in immunotherapy-treated cancer patients. In: Paper Presented at the 2026 HCSRN Annual Conference. Dallas, TX: (2026). p. 21–3. [Google Scholar]
